Lead program
Amyotrophic lateral sclerosis (ALS)
Lead indication. SRSF3-directed antisense designed to release translational repression of selected innate immune transcripts in microglia/macrophages.
Pipeline
SRSF3-directed targeted antisense.
RNOVA Tx is advancing an SRSF3 platform led by ALS, supported by a next-generation cell-targeted delivery strategy. All programs are at the research and preclinical stage.
Program Modality Indication DiscoveryLead optimizationPreclinicalIND-enablingPhase I
Lead Lead program Target: SRSF3
Targeted antisense oligonucleotide
Amyotrophic lateral sclerosis (ALS)
Stage to be confirmed
Expansion Expansion program Target: SRSF3
Targeted antisense oligonucleotide
Related neurodegenerative diseases
Stage to be confirmed
Platform EAT-ME-SRSF3 Target: SRSF3
Next-generation cell-targeted antisense
Multiple CNS opportunities
Stage to be confirmed
- Lead
Lead program
- Target
- SRSF3
- Modality
- Targeted antisense oligonucleotide
- Indication
- Amyotrophic lateral sclerosis (ALS)
- Stage
- Stage to be confirmed
Lead indication. SRSF3-directed antisense designed to release translational repression of selected innate immune transcripts in microglia/macrophages.
- Expansion
Expansion program
- Target
- SRSF3
- Modality
- Targeted antisense oligonucleotide
- Indication
- Related neurodegenerative diseases
- Stage
- Stage to be confirmed
Exploring the relevance of the SRSF3 checkpoint in neurodegenerative conditions beyond ALS.
- Platform
EAT-ME-SRSF3
- Target
- SRSF3
- Modality
- Next-generation cell-targeted antisense
- Indication
- Multiple CNS opportunities
- Stage
- Stage to be confirmed
Cell-selective delivery strategy under development, designed to improve access of SRSF3-directed antisense to selected innate immune cells.
Development stages are shown only once confirmed. A dashed track means the stage has not yet been published.
Pipeline
An SRSF3 platform, led by ALS.
Expansion program
Related neurodegenerative diseases
Exploring the relevance of the SRSF3 checkpoint in neurodegenerative conditions beyond ALS.
EAT-ME-SRSF3
Multiple CNS opportunities
Cell-selective delivery strategy under development, designed to improve access of SRSF3-directed antisense to selected innate immune cells.
No RNOVA Tx program has entered clinical trials. Program names, indications and stages will be updated as they are confirmed.
04 Targeted RNA therapeutics
Two technology pillars
Antisense strategy
TAT2-SRSF3
SRSF3-directed antisense oligonucleotides conjugated to a cell-penetrating peptide to support uptake into immune cells. Built on the target biology described in RNOVA’s published research and foundational patent.
- Target: SRSF3
- Modality: antisense oligonucleotide
- Status: research stage
Next-generation targeting
EAT-ME-SRSF3
An emerging cell-targeted delivery strategy designed to improve therapeutic access of SRSF3-directed antisense to selected innate immune cell populations.
- Cell-selective delivery under development
- Designed for innate immune cells
- Status: research stage
Advancing a new paradigm in CNS immunotherapy.
RNOVA Tx welcomes conversations with pharmaceutical, biotechnology, scientific and development partners interested in RNA therapeutics and neurodegenerative disease.